Table 1.
Comparison of the distributions of patient characteristics in the radiochemotherapy groups (30–40 mg/m2 of cisplatin weekly vs. 100 mg/m2 of cisplatin on days 1, 22 and 43; Chi-square test)
| Cisplatin weekly N patients (%) | Cisplatin 100 mg/m2 N patients (%) | P | |
|---|---|---|---|
| Age | |||
| ≤56 years (N = 67) | 37 (49) | 30 (52) | |
| ≥ 57 years (N = 66) | 38 (51) | 28 (48) | 0.92 |
| Gender | |||
| Female (N = 29) | 15 (20) | 14 (24) | |
| Male (N = 104) | 60 (80) | 44 (76) | 0.86 |
| ECOG Performance score | |||
| 0–1 (N = 115) | 64 (85) | 51 (88) | |
| 2 (N = 18) | 11 (15) | 7 (12) | 0.92 |
| Primary tumor site | |||
| Oropharynx (N = 69) | 36 (48) | 33 (57) | |
| Hypopharynx (N = 19) | 12 (16) | 7 (12) | |
| Larynx (N = 30) | 19 (25) | 11 (19) | |
| Oral cavity/Floor of mouth (N = 15) | 8 (11) | 7 (12) | 0.88 |
| T-category | |||
| T1-2 (N = 16) | 9 (12) | 7 (12) | |
| T3-4 (N = 117) | 66 (88) | 51 (88) | 0.99 |
| N-category | |||
| N0-2a (N = 66) | 39 (52) | 27 (47) | |
| N2b-3 (N = 67) | 36 (48) | 31 (53) | 0.75 |
| Histologic grading | |||
| G 1–2 (N = 85) | 49 (65) | 36 (62) | |
| G3 (N = 48) | 26 (35) | 22 (38) | 0.89 |
| Cumulative cisplatin dose | |||
| ≤200 mg/m2 (N = 85) | 51 (68) | 34 (59) | |
| >200 mg/m2 (N = 48) | 24 (32) | 24 (41) | 0.50 |
After Bonferroni correction for multiple tests (8 tests), p-values of <0.006 were considered significant